# Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma

> **NCT07692334** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Second University Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Becotatug Vedotin
- Pucotenlimab

## Interventions

- **DRUG:** Becotatug Vedotin (MRG003)
- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT07692334
- **Lead sponsor:** West China Second University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692334, "Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*